213 related articles for article (PubMed ID: 23238591)
41. [Desmopressin in hemophilia A and Von Willebrand's disease].
Castro Cabezas M; de Graaf JC; Kraayenhagen RJ; Freen M; Poortman J; Hart HC
Ned Tijdschr Geneeskd; 1991 Mar; 135(9):367-71. PubMed ID: 1901629
[TBL] [Abstract][Full Text] [Related]
42. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
Johnstone IB; Crane S
Can J Vet Res; 1987 Apr; 51(2):189-93. PubMed ID: 3111674
[TBL] [Abstract][Full Text] [Related]
43. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
44. Diagnosis and management of von Willebrand disease in Spain.
Batlle J; Perez-Rodriguez A; Pinto JC; Fraga EL; Rodriguez-Trillo Tch A; Fernanda Lopez-Fernandez M
Semin Thromb Hemost; 2011 Jul; 37(5):503-10. PubMed ID: 22102193
[TBL] [Abstract][Full Text] [Related]
45. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.
Lethagen S; Harris AS; Nilsson IM
Blut; 1990 Mar; 60(3):187-91. PubMed ID: 2107887
[TBL] [Abstract][Full Text] [Related]
46. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
Keularts IM; Hamulyak K; Hemker HC; Béguin S
Thromb Haemost; 2000 Oct; 84(4):638-42. PubMed ID: 11057863
[TBL] [Abstract][Full Text] [Related]
47. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models.
Denis CV; Kwack K; Saffaripour S; Maganti S; André P; Schaub RG; Wagner DD
Blood; 2001 Jan; 97(2):465-72. PubMed ID: 11154224
[TBL] [Abstract][Full Text] [Related]
48. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
Warrier AI; Lusher JM
J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
[TBL] [Abstract][Full Text] [Related]
49. Prophylaxis in von Willebrand disease.
Franchini M; Targher G; Lippi G
Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
[TBL] [Abstract][Full Text] [Related]
50. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
Franchini M; Mannucci PM
Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
[TBL] [Abstract][Full Text] [Related]
51. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.
Rose EH; Aledort LM
Ann Intern Med; 1991 Apr; 114(7):563-8. PubMed ID: 1900403
[TBL] [Abstract][Full Text] [Related]
52. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
53. DDAVP (desmopressin; 1-deamino-cys-8-D-arginine-vasopressin) treatment in children with haemophilia B.
Ehl S; Severin T; Sutor AH
Br J Haematol; 2000 Dec; 111(4):1260-2. PubMed ID: 11167773
[TBL] [Abstract][Full Text] [Related]
54. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
[TBL] [Abstract][Full Text] [Related]
55. A personalized approach to the management of VWD.
Phua CW; Berntorp E
Transfus Apher Sci; 2019 Oct; 58(5):590-595. PubMed ID: 31466808
[TBL] [Abstract][Full Text] [Related]
56. [Is the DDAVP-test helpful to diagnose children?].
Weissenbacher E; Acham-Roschitz B; Leschnik B; Muntean W
Hamostaseologie; 2010 Nov; 30 Suppl 1():S138-40. PubMed ID: 21042662
[TBL] [Abstract][Full Text] [Related]
57. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
58. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
59. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America.
Cohen AJ; Kessler CM; Ewenstein BM;
Haemophilia; 2001 May; 7(3):235-41. PubMed ID: 11380626
[TBL] [Abstract][Full Text] [Related]
60. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
Callan MB; Giger U; Catalfamo JL
Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
